What is the role of angiotensin-receptor blockade in cardiovascular protection?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The role of angiotensin II, the key mediator of the renin-angiotensin-aldosterone system, in the pathophysiology of cardiovascular disease is well known. Pharmacologic interruption of the activity of angiotensin II, either through blockade of the angiotensin receptor or inhibition of angiotensin-converting enzyme, is associated with a reduction in cardiovascular disease morbidity and mortality, as evidenced by accumulated data from large-scale, well-controlled clinical trials in high-risk populations. As the underlying mechanisms of vascular disease and the effects of blockade of the renin-angiotensin-aldosterone system on these processes have been further defined, the therapeutic focus has begun to shift toward prevention of disease progression at earlier stages. Continued research has identified early signs of vascular disease, such as endothelial dysfunction and vascular and cardiac remodeling, which occur long before clinical manifestations of cardiovascular disease become evident. Diagnostic tests are now available to assess otherwise healthy individuals for these signs. A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume152
Issue number5
DOIs
StatePublished - Nov 1 2006

Fingerprint

Angiotensin Receptors
Vascular Diseases
Cardiovascular Diseases
Renin-Angiotensin System
Angiotensin II
Controlled Clinical Trials
Peptidyl-Dipeptidase A
Routine Diagnostic Tests
Disease Progression
Heart Diseases
Morbidity
Mortality
Research
Population
Therapeutics

Cite this

What is the role of angiotensin-receptor blockade in cardiovascular protection? / Cohn, Jay N.

In: American Heart Journal, Vol. 152, No. 5, 01.11.2006.

Research output: Contribution to journalArticle

@article{f4ae95b81bd44c7b9439a94263b22510,
title = "What is the role of angiotensin-receptor blockade in cardiovascular protection?",
abstract = "The role of angiotensin II, the key mediator of the renin-angiotensin-aldosterone system, in the pathophysiology of cardiovascular disease is well known. Pharmacologic interruption of the activity of angiotensin II, either through blockade of the angiotensin receptor or inhibition of angiotensin-converting enzyme, is associated with a reduction in cardiovascular disease morbidity and mortality, as evidenced by accumulated data from large-scale, well-controlled clinical trials in high-risk populations. As the underlying mechanisms of vascular disease and the effects of blockade of the renin-angiotensin-aldosterone system on these processes have been further defined, the therapeutic focus has begun to shift toward prevention of disease progression at earlier stages. Continued research has identified early signs of vascular disease, such as endothelial dysfunction and vascular and cardiac remodeling, which occur long before clinical manifestations of cardiovascular disease become evident. Diagnostic tests are now available to assess otherwise healthy individuals for these signs. A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease.",
author = "Cohn, {Jay N}",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.ahj.2006.08.001",
language = "English (US)",
volume = "152",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - What is the role of angiotensin-receptor blockade in cardiovascular protection?

AU - Cohn, Jay N

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The role of angiotensin II, the key mediator of the renin-angiotensin-aldosterone system, in the pathophysiology of cardiovascular disease is well known. Pharmacologic interruption of the activity of angiotensin II, either through blockade of the angiotensin receptor or inhibition of angiotensin-converting enzyme, is associated with a reduction in cardiovascular disease morbidity and mortality, as evidenced by accumulated data from large-scale, well-controlled clinical trials in high-risk populations. As the underlying mechanisms of vascular disease and the effects of blockade of the renin-angiotensin-aldosterone system on these processes have been further defined, the therapeutic focus has begun to shift toward prevention of disease progression at earlier stages. Continued research has identified early signs of vascular disease, such as endothelial dysfunction and vascular and cardiac remodeling, which occur long before clinical manifestations of cardiovascular disease become evident. Diagnostic tests are now available to assess otherwise healthy individuals for these signs. A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease.

AB - The role of angiotensin II, the key mediator of the renin-angiotensin-aldosterone system, in the pathophysiology of cardiovascular disease is well known. Pharmacologic interruption of the activity of angiotensin II, either through blockade of the angiotensin receptor or inhibition of angiotensin-converting enzyme, is associated with a reduction in cardiovascular disease morbidity and mortality, as evidenced by accumulated data from large-scale, well-controlled clinical trials in high-risk populations. As the underlying mechanisms of vascular disease and the effects of blockade of the renin-angiotensin-aldosterone system on these processes have been further defined, the therapeutic focus has begun to shift toward prevention of disease progression at earlier stages. Continued research has identified early signs of vascular disease, such as endothelial dysfunction and vascular and cardiac remodeling, which occur long before clinical manifestations of cardiovascular disease become evident. Diagnostic tests are now available to assess otherwise healthy individuals for these signs. A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease.

UR - http://www.scopus.com/inward/record.url?scp=33750303899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750303899&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2006.08.001

DO - 10.1016/j.ahj.2006.08.001

M3 - Article

C2 - 17070145

AN - SCOPUS:33750303899

VL - 152

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -